Neuronetics, Inc. STIM
Regular-session close
After hours · Nov 19, 7:40 PM ET
- YTD
- -10.14%
- 1 year
- -16.78%
5D -0.34 (-21.12%)
- Market cap
- 119.63M
- Revenue (ttm)
- 72.06M
- Profit margin
- -45.06%
- EPS (ttm)
- -0.32
- Shares out
- 65.00M
- Forward P/E
- -2.15
- YTD return
- -10.14%
- 1-year return
- -16.78%
- 50-day average
- 1.02
- Volume
- 1.66M
- Avg volume
- 1.72M
- Open
- 1.34
- Previous close
- 1.25
- Day's range
- 1.23 – 1.34
- 52-week range
- 0.80 – 3.44
- Beta
- 2.22
- Analysts
- Buy
- Price target
- 2.67 (+115.1%)
Key statistics
- 200-day average
- 1.94
- Enterprise value
- 38.45M
- Price / sales
- 1.20
- Price / book
- 1.13
- Revenue growth
- -6.60%
- Free cash flow
- -15.35M
- Total cash
- 42.64M
- Total debt
- 62.62M
- Return on equity
- -100.13%
- Short % of float
- 2.59%
Fundamental scorecard
6 of 25 checks passed on STIM’s reported financials
6of 25 checks passed
- Value 1 of 5
- Growth 3 of 5
- Profitability 1 of 5
- Financial health 1 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.23 | -0.29 | -0.06 | -26.09% |
| Aug 12, 2024 | Jun 1, 2024 | -0.27 | -0.33 | -0.06 | -22.22% |
| Aug 12, 2024 | Jun 1, 2024 | -0.27 | — | — | — |
| May 7, 2024 | Mar 1, 2024 | -0.33 | -0.27 | +0.06 | +18.18% |
| May 7, 2024 | Mar 1, 2024 | -0.33 | — | — | — |
| Mar 5, 2024 | Dec 1, 2023 | -0.26 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 14, 2024 | JMP Securities | main | Market Outperform | Market Outperform |
| Aug 13, 2024 | Canaccord Genuity | main | Buy | Buy |
| Aug 12, 2024 | William Blair | down | Outperform | Market Perform |
| May 14, 2024 | William Blair | up | Market Perform | Outperform |
| Mar 6, 2024 | Piper Sandler | reit | Overweight | Overweight |
| May 10, 2023 | JMP Securities | reit | — | Market Outperform |
About Neuronetics, Inc.
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- neurostar.com
News
Here's Why Neuronetics (STIM) is Poised for a Turnaround After Losing 37.8% in 4 Weeks
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Neuronetics (STIM) Loses 34.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session Neuronetics Announces Credit Agreement Amendments And Public Offering Of Shares; Size Not Disclosed
B. Riley Securities Maintains Buy on Neuronetics, Raises Price Target to $6
12 Health Care Stocks Moving In Wednesday's Intraday Session
Neuronetics Q3 2026 Earnings Call Transcript
Your note
Sign in to keep a note on STIM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKEWELL JOHN K | Director | Stock Award(Grant) | May 24, 2023 | 114,352 |
| CAPPER JOSEPH H | Director | Stock Award(Grant) | May 24, 2023 | 43,147 |
| CASCELLA ROBERT A | Director | Purchase | Sep 11, 2024 | 453,098 |
| CONLEY SHERYL L | Director | Stock Award(Grant) | May 29, 2024 | 139,946 |
| FURLONG STEPHEN | Chief Financial Officer | Sale | Oct 7, 2024 | 497,408 |
| JAEGER WILFRED E | Director | Stock Award(Grant) | May 24, 2023 | 138,563 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Kent Lake PR LLC | 6.85% | 2,077,848 | 2.76M | Sep 29, 2024 |
| Cannell Capital LLC | 4.33% | 1,314,266 | 1.75M | Sep 29, 2024 |
| Vanguard Group Inc | 4.28% | 1,299,915 | 1.73M | Sep 29, 2024 |
| Masters Capital Management, LLC | 3.95% | 1,200,000 | 1.60M | Sep 29, 2024 |
| Balyasny Asset Management LLC | 3.77% | 1,144,232 | 1.52M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.92% | 581,800 | 773.79K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| First Eagle Small Opportunity Fund | 3.16% | 957,815 | 1.27M | Jul 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.80% | 849,497 | 1.13M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.33% | 403,878 | 537.16K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.53% | 162,067 | 215.55K | Oct 30, 2024 |
| EQ Advisors Trust-1290 VT Gamco Small Company Value Port | 0.25% | 75,000 | 99.75K | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.20% | 62,048 | 82.52K | Oct 30, 2024 |
